ClinicalTrials.gg
Active, not recruitingNCT07331402Updated Jan 9, 2026

A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

A Phase 2 interventional study of HSK39004 inhalation suspension in COPD Patients, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. — 6 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Haisco Pharmaceutical Group Co., Ltd..

Planned enrollment
10th of 10
12 · median 300
Started
2025
with 2 others
Phase 2
6 of 10
3 open now
Registered
6th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd., this one is the 10th largest by planned enrollment, is one of 3 that started in 2025, is one of 6 in phase 2, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd., or all of them as a file.
02

Study summary

This is a random, single blind, positive control, crossover design clinical study to evaluate the pharmacokinetics and pharmacodynamics of HSK39004 inhalation suspension in COPD patients

03

Conditions studied

  • COPD Patients
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • During the screening visit (Visit 1), the age range is 40 to 80 years (including the threshold value), and gender is not restricted;
  • The subjects with (COPD) as per the GOLD 2025 diagnostic criteria, and the symptoms before screening were consistent with COPD for at least 1 year [GOLD 2025 standard: the subjects have chronic respiratory symptoms such as shortness of breath, chronic cough or expectoration, and/or have a history of exposure to risk factors, and the pulmonary function test results show: the (FEV1) after using bronchodilators / forced vital capacity (FVC) \<0.7];
  • During the screening visit (Visit 1):· FEV1/FVC after using bronchodilators is \<0.7;· 30% of the expected value ≤ FEV1 after using bronchodilators \< 80% of the expected value;
  • COPD stable within 4 weeks prior to screening period (Visit 1);
  • During the screening period and treatment period, COPD drugs prohibited by the protocol (except for salbutamol inhalation aerosol as a rescue drug) can be discontinued;
  • Current smokers with a smoking quantity of ≥ 10 packs per year (smoking index (pack years) = daily smoking quantity (packs) × time (years), 1 pack = 20 cigarettes), or quit smoking for more than 6 months, or those with a history of exposure to other risk factors;
  • Participants voluntarily sign the form;

Exclusion criteria

Exclusion Criteria:

  • Have a history of life-threatening , including being admitted to the intensive care unit and/or requiring intubation;
  • Have received treatment for COPD acute exacerbation for pneumonia within 12 weeks before screening;
  • Have a history of or currently have severe cardiovascular diseases;
  • Have type I diabetes or poorly controlled type II diabetes (fasting blood glucose ≥ 10 mmol/L at screening);
  • Have cancer (in situ cancer that has been cured for more than 5 years, skin squamous cell carcinoma and basal cell carcinoma, etc., except for subjects with suspected malignant tumors or undetermined tumors);
  • Combine other severe unstable kidney, nervous system, endocrine diseases, thyroid diseases, urinary system, ophthalmic diseases, immune system, mental system, gastrointestinal, liver or blood system disease/abnormal history, as determined by the investigator, participation in this study may pose risks to the subjects or affect the analysis of research results;
  • During the screening period (visit 1), the investigator determines that the laboratory tests of the subjects show abnormalities that may pose risks to the subjects;
  • Allergy to HSK39004 inhalation powder or salbutamol or any known components in the administration system ; 8. Before the pulmonary function test during the screening (visit 1), any prohibited drugs in the protocol were used;
  • During the screening period, there were clinically significant abnormalities in the 12 lead that were determined by the researchers to be potentially risky for the subjects;
  • Had major surgery (requiring general anesthesia) within 6 weeks before screening, not fully recovered at the time of screening, or planned to undergo surgery before the end of the study;
  • Pregnant or lactating women, or female subjects with positive pregnancy test results;
  • Researchers determine other subjects who are not suitable to participate.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    HSK39004- Ohtuvayre

    The first period, HSK39004 inhalation suspension , Inhale through the mouth, 3mg each time, twice a day; The second period,Ohtuvayre inhalation suspension, Inhale through the mouth, 3mg each time, twice a day

    Drug: HSK39004 inhalation suspension

  • Other
    Ohtuvayre - HSK39004

    The first period,Ohtuvayre inhalation suspension, Inhale through the mouth, 3mg each time, twice a day; The second period,HSK39004 inhalation suspension , Inhale through the mouth, 3mg each time, twice a day.

    Drug: HSK39004 inhalation suspension

Interventions

  • HSK39004 inhalation suspension , Inhale through the mouth, 3mg each time, twice a day; Ohtuvayre inhalation suspension, Inhale through the mouth, 3mg each time, twice a day

    Also known as: Ohtuvayre inhalation suspension

06

What researchers measure

Primary outcomes

  1. The Cmax after single administrations

    The Cmax of HSK39004 in plasma

    Time frame: [Time Frame: From the start of administration to 12 hours post-dose]

  2. The Css(max) after multiple administrations (steady state)

    The Css(max) of HSK39004 in plasma

    Time frame: [Time Frame: From the start of administration to 7 days post-dose]

Secondary outcomes

  1. The ΔFEV1 AUC0-12h

    The area under the curve of FEV1 change from baseline from 0 to 12 hours after administration

    Time frame: [Time Frame: From the start of administration to 12 hours post-dose on Day1 and Day7]

  2. AEs

    The incidence and severity of AEs

    Time frame: [Time Frame: From the time of signing ICF to the end of follow-up,up to 7 days after the last administration]

07

Study locations

1 site
  • 36 Sanhao Street, Heping District, Shenyang, Liaoning,China
    Shenyang, Liaoning, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 5 months after the start.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 5 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Jan 9, 2026
StartActual
Jul 28, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Aug 30, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07331402
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jul 28, 2025
Primary completion
Dec 30, 2025 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39004

Start the discussion